Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1-FV in a randomized controlled trial by unknown
Klimek et al. Clinical and Translational Allergy  (2015) 5:28 
DOI 10.1186/s13601-015-0071-xBRIEF COMMUNICATION Open AccessAllergy immunotherapy with a
hypoallergenic recombinant birch pollen allergen
rBet v 1-FV in a randomized controlled trial
Ludger Klimek1*, Claus Bachert2, Karl-Friedrich Lukat3, Oliver Pfaar1, Hanns Meyer4 and Annemie Narkus4Abstract
Background: Pollen extracts and chemically modified allergoids are used successfully in allergen immunotherapy
(AIT). Recombinant extracts offer potential advantages with respect to pharmaceutical quality, standardization and
dosing. A hypoallergenic recombinant folding variant of the major birch pollen allergen (rBet v 1-FV) was compared
with an established native birch preparation. A pre-seasonal, randomized, actively controlled phase II study was
performed in birch pollen allergic rhino-conjunctivitis with or without asthma, GINA I/ II. 51 patients (24 rBet v 1-FV,
27 native extract) started therapy with subcutaneous allergen immunotherapy (SCIT). Primary end-point was a
combined symptom medication score (SMS), changes in nasal provocation test, visual rating score and specific
antibody responses secondary end-points.
Findings: After one pre-seasonal treatment course the combined SMS was 5.86 (median; IQR: 14.02) for the rBet v
1-FV group versus 12.40 (median; IQR: 9.32) for the comparator during the three weeks pollen season (p = 0.330).
After treatment in the second year, scores were 3.00 (median; IQR: 6.50) and 2.93 (4.86) respectively. Allergen
tolerance in a nasal provocation test improved to a comparable extent in both groups. Significant increases in birch
pollen-specific IgG1 and IgG4 were observed in both treatment groups following the first treatment phase and
remained significantly raised until the end of the study.
Conclusion: In this first in man, proof of concept phase II trial no statistical difference between rBet v 1-FV and an
established natural pollen extract could be observed. rBet v 1-FV could be administered in higher doses than the
native protein with no increase in adverse effects.
Trial registration: The study was registered in clinicalTrials.gov (NCT00266526).
Keywords: Allergy immunotherapy, Subcutaneous immunotherapy, Birch pollen, Allergic rhinitis, Rhino-conjunctivitis,
Birch pollen, Recombinant Bet v 1, Hypoallergenic variant, Folding variant, Recombinant allergenIntroduction
Subcutaneous immunotherapy (SCIT) has been shown to
be clinically efficacious in numerous controlled clinical
studies and is the only curative approach towards allergy
treatment recommended in a WHO Position Paper [1].
Recombinant preparations are an ideal basis for devel-
opment of diagnostic and therapeutic preparations, since
they are molecularly defined and can be produced in high
purity with consistent quality, thereby circumventing* Correspondence: ludger.klimek@allergiezentrum.org
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extracts and their standardization.
In order to reduce the risk of IgE-mediated therapy-
induced side effects a folding variant of recombinant Bet
v 1 (rBet v 1-FV), the major birch pollen allergen, has
been developed [2].
This is the first report of a randomized, controlled, proof
of concept study comparing two pre-seasonal treatment
courses of SCIT with either rBet v 1-FV or an approved
native birch pollen depot extract. The objective of thele is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
Klimek et al. Clinical and Translational Allergy  (2015) 5:28 Page 2 of 8study was to determine the safety and efficacy of the re-
combinant preparation, and to investigate whether treat-
ment with a single major allergen as opposed to a whole
extract can be clinically effective.
The publication is performed according to CONSORT
guidelines.Fig. 1 Flow chart documenting progress through the study of those patienMaterials and methods
The study was performed in accordance with the Guide-
lines for Good Clinical Practice [3] and approval of local
ethics committees.
Treatment was conducted between October and
March in two consecutive years. Dosage was increasedts included in the main data sets
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adsorbed rBet v 1-FV [4] (5 μg/mL Strength A,
100 μg/mL Strength B) at 7-day intervals, cumulative
dose 157.5 μg; comparator: 14 injections, 3 strengths
(50, 500 and 5,000 (therapeutic units) TU/mL), 16,325
TU, and continued until the onset of the birch pollen
seasons.
Patients with birch pollen rhino-conjunctivitis, with or
without asthma (GINA 1 or 2 [5]), requiring medication
during the previous pollen season, with positive skin prick
test for birch, specific IgE-RAST ≥ 2 (ImmunoCAP®) and a
positive nasal provocation test (NPT) [6], fulfilling usual
AIT exclusion criteria, were recruited (Fig. 1).
Determination of outcome measures required that sub-
jects achieved an adequate dose, defined as either at least
one injection of the maintenance dose of rBet v 1-FV
(strength B/0.8 mL, 80 μg) or 13 injections of the compara-
tor (Novo-Helisen® Depot birch pollen, Allergopharma
GmbH & Co. KG) with at least one dose of 2,000 TU.
Main data set in the first year: 39 subjects (rBet v 1-FV
22, comparator 17), second year: 17 and 14 of those sub-
jects respectively. Demographic data is shown in Table 1.
Adverse events were coded according to the Medical
Dictionary for Regulatory Activities (MedDRA).
Symptom Medication Score (SMS) in the birch pollen
seasons was the primary outcome measure for efficacy,
using a validated score [7]. Subjects had access to short-
acting, non-prophylactic symptomatic medication (short-
acting topical antihistamine as first-line treatment, oral
antihistamine for more severe symptoms; short-acting
bronchodilator for asthma and inhaled steroids scored
only if dose was changed).Table 1 Demographic and baseline data
rBet
n = 2
Gender (n) M/F 10/1
Age (years) Mean ± SD 41.00
Range 20–6
Bet v 1 specific IgE at recruitment out of season (kUA/L) Mean ± SD 21.79
Range 0.6–1
Allergic symptoms
Conjunctivitis n (%) 24 (1
Rhinitis n (%) 24 (1
Cough/sibilant rhonchi n (%) 6 (25
Allergic asthma n (%) 9 (38
Atopic dermatitis n (%) 1 (4
Duration of symptoms (years) Mean ± SD 11.75
Range 1–43
Median SMS on 15th March first treatment yeara 3.0
n.a.: not available; afirst day on which SMS data was collectedFinal evaluation was based on a 21-day period of main
birch pollen exposure (median area under the curve
(AUC), 7 days before until 13 days after peak pollen count).
Nasal provocation test was performed at inclusion and
prior to the birch pollen seasons according German guide-
line [6].Immunoglobulin measurements
Birch pollen, Bet v 1, 2 and 4 specific IgE was measured
at inclusion (ImmunoCAP®), birch pollen specific IgG1,
IgG4 and IgE responses by ELISA [8]: 1, screening be-
fore SCIT; 2, after up-dosing first season; 3, after first
pollen season; 4, after up-dosing second season; and 5,
after second pollen season.
Pollen counts were provided by the European Aeroaller-
gen Network (https://ean.polleninfo.eu/Ean/, (siegfried.jae
ger@meduniwien.ac.at).Reference group
34 subjects participating in the baseline year of a separate
birch pollen SCIT study being conducted under identical
conditions in the same geographical region of Germany.Statistical analysis
The AUC for the treatment groups were compared using
confidence intervals to draw conclusions on possible su-
periority, non-inferiority or equivalence of efficacy. The
two-sided Wilcoxon-Mann–Whitney U-Test at α = 0.05
was applied in the analysis of antibody responses using
SPSS Version 14.02 (SPSS Inc., Chicago, USA).v 1-FV Comparator birch pollen depot preparation Reference group
4 n = 27 n = 34
4 13/14 10/24
± 12.28 37.70 ± 9.83 38.38 ± 11.58
3 22–60 23–59
± 24.96 21.28 ± 39.76 n.a.
01.2 0.7–168.1
00 %) 27 (100 %) 34 (100 %)
00 %) 26 (96 %) 34 (100 %)
%) 3 (11 %) 20 (59 %)
%) 11 (41 %) 15 (44 %)
%) 0 (0 %) 4 (12 %)
± 10.86 12.52 ± 9.34 14.09 ± 6.45
1–33 2–26
3.0 5.5
Fig. 2 Course of daily median SMS and median pollen counts during the 21-day observational periods in the birch pollen season after one
(above) and two courses (below) of SCIT, respectively
Table 2 Median AUC of the symptom scores, medication scores and combined SMS for the 21 day observation period during main
birch pollen exposure in each of the two seasons
rBet v 1-FV Comparator Wilcoxon–Mann–Whitney U-Test
median (IQR) median (IQR) p-values
First treatment year
Symptom score 3.10 (9.36) 5.69 (4.71) 0.400
Medication score 1.43 (3.10) 2.83 (5.75) 0.285
SMS 5.86 (14.02) 12.40 (9.32) 0.330
Second treatment year
Symptom score 2.81 (4.02) 1.67 (2.41) 0.393
Medication score 0.29 (1.36) 1.05 (3.50) 0.730
SMS 3.00 (6.50) 2.93 (4.86) 0.812
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Application of study medication
265 rBet v 1-FV injections were administered during the
first treatment year, 228 during 2nd year (median 11 and
12 per patient); comparator 349 and 353 (median 14 and
18). The maximum dose of 80 μg rBet v 1-FV was
achieved in 22/24 subjects in the 1st year, one achieved
20 μg, one 4 μg (2nd year: 17 (80 μg), 2 (2 μg)). Only 7/27
subjects achieved the recommended dose of 5,000 TU
with the comparator, equivalent to 16 μg natural Bet v 1,
4/27 achieving 4,000 TU, 7/27 3,000 TU, 4/27 2,000 TU
and 5/27 1,000 TU or less (2nd year: 18 (5,000 TU), 3
(4,000/3,000/40 TU).Symptom medication score (SMS)
With a peak pollen count of 834 grains/m3 during the
first pollen season the median AUC of SMS for the
rBet v 1-FV group was 5.86 (IQR: 14.02), substantially
lower than the 12.40 (IQR: 9.32) recorded for the com-
parator group (p = 0.330), reference group 14.67 (IQR:
13.64) (Table 2 & Fig. 2).
Substantial cross-reacting tree pollen counts occurred
during the few weeks prior to the 21 day observation
period, and probably accounted for the differences in
SMS at the beginning of the 21 day observation period
(7th April) (Fig. 2). The median SMS values for the three
groups on 15th March, the first day on which data was
collected, were 3.0, 3.0 and 5.5 respectively.
In the second year (peak pollen count 827 grains/m3)
the median SMS for the rBet v 1-FV and comparator
groups were 3.00 (IQR: 6.50) and 2.93 (IQR: 4.86) re-
spectively (Table 2).Specific antibody responses
Baseline birch pollen-specific IgE levels as well as levels
during treatment were similar for rBet v 1-FV and the
comparator groups; IgG1 and IgG4 levels were compar-
able at baseline, showed significant increases with mar-
ginally stronger responses in the rBet v 1-FV group
(Fig. 3) and further increases in the second year.Fig. 3 Birch pollen-specific IgE, IgG1 and IgG4 concentrations.
Median values with 25th/75th and 10th/90th percentiles represented
by boxes and error bars respectively, outliers by points. Time points:
1, screening before SCIT; 2, after up-dosing first year; 3, after pollen
season first year; 4, after up-dosing second year; and 5, after pollen
season second yearNasal provocation test
At entry there were no significant differences between
the two groups in NPT. An enhanced tolerance thresh-
old, with at least a three-fold increase in the tolerated
allergen concentration, was seen in 8/15 subjects in
the rBet v 1-FV group (8/14 comparator) after SCIT in
the first year. In the second year enhanced tolerance
was seen in 11/12 rBet v 1-FV (1 subject showing no
change), as compared with only 6/11 in the compara-
tor group (3 subjects no change, 2 deterioration
(Table 3)).Adverse events
During the two pre-seasonal treatment courses at least
one local or systemic reaction with at least possible rela-
tionship to trial medication was recorded in 22/24
(91.7 %) of the rBet v 1-FV treated subjects and 23/27
Table 3 Nasal provocation test response thresholds
A
rBet v 1-FV Threshold response after treatment in 1st year
BU/mL 555 1,666 5,000 15,000 45,000 150,000 negative
Threshold response at baseline 555 3 3 0 0 0 0 1
1,666 1 2 1 2 0 0 0
5,000 0 1 0 1 0 0 0
15,000 0 0 0 0 0 0 0
45,000 0 0 0 0 0 0 0
rBet v 1-FV Threshold response after treatment in 2nd year
BU/mL 555 1,666 5,000 15,000 45,000 150,000 negative
Threshold response at baseline 555 0 4 0 2 0 0 0
1,666 0 0 2 0 1 1 0
5,000 0 0 1 0 0 1 0
15,000 0 0 0 0 0 0 0
45,000 0 0 0 0 0 0 0
B
Comparator Threshold response after treatment in 1st year
BU/mL 555 1,666 5,000 15,000 45,000 150,000 negative
Threshold response at baseline 555 0 0 2 0 0 0 0
1,666 2 2 3 1 0 0 0
5,000 0 1 0 0 2 0 0
15,000 0 0 0 0 0 0 0
45,000 0 0 0 1 0 0 0
Comparator Threshold response after treatment in 2nd year
BU/mL 555 1,666 5,000 15,000 45,000 150,000 negative
Threshold response at baseline 555 1 0 0 0 0 0 0
1,666 1 1 4 0 0 0 0
5,000 0 0 1 0 1 0 1
15,000 0 0 0 0 0 0 0
45,000 0 0 0 1 0 0 0
Data indicate numbers of subjects and their responses at baseline compared with that after 1 year or 2 years of treatment with (A) rBet v 1-FV or (B) comparator
Bold printed numbers represent no change in response, and data to the right or the left an increase or decrease in tolerance respectively
Klimek et al. Clinical and Translational Allergy  (2015) 5:28 Page 6 of 8(85.2 %) of comparator; systemic reactions in 42 % of
rBet v 1-FV, 41 % comparator.
Two serious adverse events occurred during the study,
both in the same patient on the same day 5 weeks after
administration of the last rBet v 1-FV injection (bursitis,
acute exacerbation right shoulder and trigger-thumb
right) being assessed as not treatment related.
All reactions (Table 4) are grouped according Med-
DRA system organ classes.
Discussion
This is the first in man clinical study using a hypoaller-
genic recombinant folding-variant of Bet v 1 for the
treatment of seasonal allergy. The study was designed asa randomized, controlled trial to determine potential
clinical efficacy by open comparison (because of differ-
ent up-dosing schemes) with an established birch pollen
preparation.
The median daily SMS for the rBet v 1-FV group was
substantially less than that for the birch pollen extract
treated group 5.86 (median; IQR: 14.02) as compared
with 12.40 (median; IQR: 9.32) after the first pre-
seasonal treatment. This difference equates to the daily
use of one tablet anti-histamine. During the 2nd pollen
season the SMS for the two groups were very compar-
able, indicating that the whole pollen extract was able to
achieve the same effect as the recombinant molecule,
but took longer to do so. The difference in SMS was not
Table 4 Adverse events reported with a least a possible relationship to SCIT for both study groups, classified in accordance with
MedDRA
System organ class AEs reported (Preferred terms) rBet v 1-FV (n = 24) Comparator (n = 27)
No. of patients with at
least one AE (%)
No. of
Events
No. of patients with at
least one AE (%)
No. of
Events
Cardiac disorders Cardiovascular disorder 1 (4) 1 0 (0) 0
Eye disorders Eye pruritus, Lacrimation increased,
Conjunctivitis
2 (8) 3 3 (11) 3
Gastrointestinal disorders Oral pruritus, Nausea 1 (4) 1 1 (4) 1
General disorders and
administration site conditions
Fatigue, Injection site erythema, Injection
site swelling, Injection site pruritus, Injection
site induration, Injection site pain, Injection
site warmth
16 (67) 101 20 (74) 151
Immune system disorders Eyelid oedema, CSF monocyte count,
Conjunctivitis allergic, Rhinitis allergic,
Urticaria, Allergic cough, Asthma
7 (29) 23 5 (19) 11
Infections and infestations Herpes simplex, Rhinitis 2 (8) 3 2 (7) 2
Investigations Peak expiratory flow rate decreased 1 (4) 1 1 (4) 2
Psychiatric disorders Nervousness 0 (0) 0 1 (4) 1
Respiratory, thoracic and
mediastinal disorders




3 (12) 5 7 (26) 12
Skin and subcutaneous tissue
disorders
Erythema, Exanthem, Neurodermatitis,
Rash pruritic, Swelling face, Urticaria,
Urticaria generalised
6 (25) 8 1 (4) 1
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was a first in man study with a totally new product and
because of safety reasons not powered to demonstrate
differences between treatments. However, the lack of
power calculation and the absence of a placebo group is
an important limitation as it prevents any direct assess-
ment of the significance of the clinical improvement.
The comparison with a reference group from the same
geographical region from the baseline season of a phase
III trial with rBet v 1-FV (NCT00309062) helps to put
the data into perspective.
The enhanced tolerance threshold compared with
baseline in NPT after the 2nd treatment course was
more pronounced in rBet v 1-FV (11/12 subjects) com-
pared to NHD (6/11). Single pre-seasonal treatments
with either hypoallergenic fragments or a trimeric form
of recombinant Bet v 1 showed increased tolerance
within the groups, but not in comparison to placebo [9].
The advantage in favor of the recombinant preparation
in the present study may reflect the higher therapeutic
dose and/or its superior efficacy.
There were no significant changes in birch pollen or
Bet v 1 specific IgE in either group, although a slight
downward trend was apparent in the 2nd year of the
study. Such decreases have been seen with longer treat-
ment protocols including recombinant grass pollen
allergens after 20 months of therapy [10], and pre-
seasonal treatment with a grass pollen allergoid over2 years [11]. These results suggest that AIT can cause
at least partial suppression of those Th2 cytokines es-
sential for IgE-production.
The large and significant increases of birch pollen spe-
cific IgG4 levels at maximum dosing, indicate that
rBet v 1-FV has a strong immunogenic effect, slightly in
excess of that of the allergen extract; possibly explained
by the random coil structure facilitating processing by
antigen presenting cells [12].
The rBet v 1-FV was well tolerated and the safety
profile was comparable with that of the natural pollen
preparation. A permanent dose-reduction was not ne-
cessary in subjects with systemic reactions, and the
maintenance dose of 80 μg protein could be realized in
nearly all subjects. The comparable safety data with the
two preparations in the present study, despite the five-
fold higher major allergen dose of the recombinant
preparation, indicates a possible advantage for the
hypoallergenic rBet v 1-FV.
This first in man proof of concept clinical study of
SCIT using a folding-variant of an rBet v 1- vaccine for
the treatment of seasonal hay fever has demonstrated
good clinical tolerance and efficacy after just one pre-
seasonal course comparable to a native birch pollen
preparation. The induction of strong allergen-specific
IgG antibody responses demonstrates the immunogen-
icity of the rBet v 1-FV and confirms that the hypo-
allergenic characteristics are not detrimental to its
Klimek et al. Clinical and Translational Allergy  (2015) 5:28 Page 8 of 8immune-modulatory potential. Subsequent clinical DBPC-
trials are warranted to confirm its clinical efficacy.
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